1.Hunder NN，Wallen H，Cao J，et al.Treatment of metastatic melanoma with autologous CD4 ⁺T cells against NY-ESO-1.The New England journal of medicine，2008，358：2698-2703.

2.Iliopoulou EG，Kountourakis P，Karamouzis MV，et al.A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer.Cancer immunology，immunotherapy：CⅡ，2010，59：1781-1789.

3.Parkhurst MR，Riley JP，Dudley ME，et al.Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.Clinical cancer research：an official journal of the American Association for Cancer Research，2011，17：6287-6297.

4.Schioppa T，Moore R，Thompson RG，et al.B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis.Proceedings of the National Academy of Sciences of the United States of America，2011，108：10662-10667.

5.Senovilla L，Vacchelli E，Galon J，et al.Trial watch：Prognostic and predictive value of the immune infiltrate in cancer.Oncoimmunology，2012，1：1323-1343.

6.Rosenberg SA，Lotze MT，Muul LM，et al.A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.Surgery，1986，100：262-272.

7.Rosenberg SA.Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know.Nature reviews Clinical oncology，2011，8：577-585.

8.Phan GQ，Rosenberg SA.Adoptive cell transfer for patients with metastatic melanoma：the potential and promise of cancer immunotherapy.Cancer control：journal of the Moffitt Cancer Center，2013，20：289-297.

9.Itzhaki O，Levy D，Zikich D，et al.Adoptive T-cell transfer in melanoma.Immunotherapy，2013，5：79-90.

10.Radvanyi LG，Bernatchez C，Zhang M，et al.Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.Clinical cancer research：an official journal of the American Association for Cancer Research，2012，18：6758-6770.

11.Rosenberg SA，Yang JC，Sherry RM，et al.Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.Clinical cancer research：an official journal of the American Association for Cancer Research，2011，17：4550-4557.

12.Itzhaki O，Hovav E，Ziporen Y，et al.Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy.Journal of immunotherapy，2011，34：212-220.

13.Mazumder A，Rosenberg SA.Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.The Journal of experimental medicine，1984，159：495-507.

14.Rosenberg SA，Lotze MT，Muul LM，et al.Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.The New England journal of medicine，1985，313：1485-1492.

15.Rosenberg SA，Lotze MT，Yang JC，et al.Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.Annals of surgery，1989，210（4）：474-484.

16.Kotasek D，Vercellotti GM，Ochoa AC，et al.Lymphokine activated killer（LAK）cell-mediated endothelial injury：a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2.Transactions of the Association of American Physicians，1987，100：21-27.

17.Yun YS，Hargrove ME，Ting CC.In vivo antitumor activity of anti-CD3-induced activated killer cells.Cancer research，1989，49：4770-4774.

18.Curti BD，Longo DL，Ochoa AC，et al.Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.Journal of clinical oncology：official journal of the American Society of Clinical Oncology，1993，11：652-660.

19.Schmidt-Wolf IG，Negrin RS，Kiem HP，et al.Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.The Journal of experimental medicine，1991，174：139-149.

20.June CH，Maus MV，Plesa G，et al.Engineered T cells for cancer therapy.Cancer immunology，immunotherapy：CⅡ，2014，63：969-975.

21.Barrett DM，Singh N，Porter DL，et al.Chimeric antigen receptor therapy for cancer.Annual review of medicine，2014，65：333-347.

22.Hudecek M，Sommermeyer D，Kosasih PL，et al.The non-signaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.Cancer immunology research 2014.

23.Jensen MC，Riddell SR.Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.Immunological reviews，2014，257：127-144.

24.Shirasu N，Kuroki M.Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer：architecture and outcomes.Anticancer research，2012，32：2377-2383.

25.Sadelain M，Brentjens R，Riviere I.The basic principles of chimeric antigen receptor design.Cancer discovery，2013，3：388-398.

26.Vacchelli E，Eggermont A，Fridman WH，et al.Trial Watch：Adoptive cell transfer for anticancer immunotherapy.Oncoimmunology，2013，2：e24238.

27.Hinrichs CS，Rosenberg SA.Exploiting the curative potential of adoptive T-cell therapy for cancer.Immunological reviews，2014，257：56-71.

28.Rosenberg SA.Finding suitable targets is the major obstacle to cancer gene therapy.Cancer gene therapy，2014，21：45-47.

29.Kawakami Y，Eliyahu S，Delgado CH，et al.Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.Proceedings of the National Academy of Sciences of the United States of America，1994，91：3515-3519.

30.Kawakami Y，Eliyahu S，Delgado CH，et al.Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.Proceedings of the National Academy of Sciences of the United States of America，1994，91：6458-6462.

31.Johnson LA，Morgan RA，Dudley ME，et al.Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.Blood，2009，114：535-546.

32.Parkhurst MR，Yang JC，Langan RC，et al.T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.Molecular therapy：the journal of the American Society of Gene Therapy，2011，19：620-626.

33.Morgan RA，Yang JC，Kitano M，et al.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.Molecular therapy：the journal of the American Society of Gene Therapy，2010，18：843-851.

34.Xu XJ，Tang YM.Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells.Cancer letters，2014，343：172-178.

35.Kochenderfer JN，Wilson WH，Janik JE，et al.Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.Blood，2010，116：4099-4102.

36.Kochenderfer JN，Rosenberg SA.Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.Nature reviews Clinical oncology，2013，10：267-276.

37.Maude SL，Frey N，Shaw PA，et al.Chimeric antigen receptor T cells for sustained remissions in leukemia.The New England journal of medicine，2014，371：1507-1517.

38.Robbins PF，Morgan RA，Feldman SA，et al.Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2011，29：917-924.

39.Morgan RA，Chinnasamy N，Abate-Daga D，et al.Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.Journal of immunotherapy，2013，36：133-151.

40.Morgan RA，Johnson LA，Davis JL，et al.Recognition of glioma stem cells by genetically modified T cells targeting EGFRvⅢand development of adoptive cell therapy for glioma.Human gene therapy，2012，23：1043-1053.

41.Sampson JH，Choi BD，Sanchez-Perez L，et al.EGFRvⅢmCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.Clinical cancer research：an official journal of the American Association for Cancer Research，2014，20：972-984.

42.Bollard CM，Gottschalk S，Torrano V，et al.Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.Journal of clinical oncology：official journal of the American Society of Clinical Oncology，2014，32：798-808.

43.Tjalma WA，Depuydt CE.Cervical cancer screening：which HPV test should be used--L1 or E6/E7？European journal of obstetrics，gynecology，and reproductive biology，2013，170：45-46.

44.Chinnasamy D，Yu Z，Theoret MR，et al.Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.The Journal of clinical investigation，2010，120：3953-3968.

45.Tran E，Chinnasamy D，Yu Z，et al.Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia.The Journal of experimental medicine，2013，210：1125-1135.

46.Vogelstein B，Papadopoulos N，Velculescu VE，et al.Cancer genome landscapes.Science，2013，339：1546-1558.

47.Robbins PF，Lu YC，El-Gamil M，et al.Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.Nature medicine，2013，19：747-752.

48.Lu YC，Yao X，Crystal JS，et al.Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.Clinical cancer research：an official journal of the American Association for Cancer Research，2014，20：3401-3410.

49.Plotkin SA.Vaccines：past，present and future.Nature medicine，2005，11：5-11.

50.Klebanoff CA，Acquavella N，Yu Z，et al.Therapeutic cancer vaccines：are we there yet？Immunological reviews，2011，239：27-44.

51.Mellman I，Coukos G，Dranoff G.Cancer immunotherapy comes of age.Nature，2011，480：480-489.

52.Melero I，Gaudernack G，Gerritsen W，et al.Therapeutic vaccines for cancer：an overview of clinical trials.Nature reviews Clinical oncology，2014，11：509-524.

53.Heicappell R，Schirrmacher V，von Hoegen P，et al.Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells.Ⅰ.Parameters for optimal therapeutic effects.International journal of cancer Journal international du cancer，1986，37：569-577.

54.Schirrmacher V，Heicappell R.Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells.Ⅱ.Establishment of specific systemic anti-tumor immunity.Clinical & experimental metastasis，1987，5：147-156.

55.von Hoegen P，Heicappell R，Griesbach A，et al.Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells.Ⅲ.Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals.Invasion & metastasis，1989，9：117-133.

56.Schirrmacher V，Haas C，Bonifer R，et al.Human tumor cell modification by virus infection：an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus.Gene therapy，1999，6：63-73.

57.Ward JE，McNeel DG.GVAX：an allogeneic，whole-cell，GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer.Expert opinion on biological therapy，2007，7：1893-1902.

58.Lubaroff DM.Prostate cancer vaccines in clinical trials.Expert review of vaccines，2012，11：857-868.

59.Palucka K，Banchereau J，MellmanⅠ.Designing vaccines based on biology of human dendritic cell subsets.Immunity，2010，33：464-478.

60.Palucka K，Banchereau J.Dendritic-cell-based therapeutic cancer vaccines.Immunity，2013，39：38-48.

61.Butterfield LH.Dendritic cells in cancer immunotherapy clinical trials：are we making progress？Frontiers in immunology，2013，4：454.

62.Kantoff PW，Higano CS，Shore ND，et al.Sipuleucel-T immunotherapy for castration-resistant prostate cancer.The New England journal of medicine，2010，363：411-422.

63.Ahmed MS，Bae YS.Dendritic cell-based therapeutic cancer vaccines：past，present and future.Clinical and experimental vaccine research，2014，3：113-116.

64.Miah MA，Byeon SE，Ahmed MS，et al.Egr2 induced during DC development acts as an intrinsic negative regulator of DC immunogenicity.European journal of immunology，2013，43：2484-2496.

65.Hong B，Lee SH，Song XT，et al.A super TLR agonist to improve efficacy of dendritic cell vaccine in induction of anti-HCV immunity.PloS one，2012，7：e48614.

66.Zhang SN，Choi IK，Huang JH，et al.Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF.Molecular therapy：the journal of the American Society of Gene Therapy，2011，19：1558-1568.

67.Ou X，Cai S，Liu P，et al.Enhancement of dendritic celltumor fusion vaccine potency by indoleamine-pyrrole 2，3-dioxygenase inhibitor，1-MT.Journal of cancer research and clinical oncology，2008，134：525-533.

68.Li Y，Xu J，Zou H，Wang C.1-MT enhances potency of tumor cell lysate-pulsed dendritic cells against pancreatic adenocarcinoma by downregulating the percentage of Tregs.Journal of Huazhong University of Science and Technology Medical sciences = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban，2010，30：344-348.

69.Cannon MJ，Goyne HE，Stone PJ，et al.Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4 ⁺Th17 responses to ovarian tumor antigen.Cancer immunology，immunotherapy：CII，2013，62：839-849.

70.Hacohen N，Fritsch EF，Carter TA，et al.Getting personal with neoantigen-based therapeutic cancer vaccines.Cancer immunology research，2013，1：11-15.